IVF

I. CRYSTALLOID FLUIDS

1. Normal Saline (0.9% NaCl)

MOA

• Isotonic fluid

• Expands extracellular fluid (ECF) → stays in intravascular & interstitial spaces

• No shift into cells (no osmotic pull)

Indications

• Hypovolemia / dehydration

• Shock

• Hyponatremia

• DKA (initial fluid)

• Blood transfusions (only fluid compatible)

• Sepsis fluid resuscitation

Contraindications / Cautions

• Hyperchloremic metabolic acidosis

• Heart failure

• Renal failure → risk of fluid overload

• Avoid large volumes in traumatic brain injury (increases chloride → worsens acidosis)

2. Lactated Ringers (LR)

MOA

• Isotonic balanced crystalloid

• Contains Na, K, Ca, Cl + lactate (converted to bicarbonate by liver)
  → Buffers acidosis, expands ECF.

Indications

• Surgery

• Burns

• Trauma

• GI fluid loss

• Metabolic acidosis

Contraindications / Cautions

• Liver failure (cannot metabolize lactate → lactic acidosis)

• Hyperkalemia (contains K⁺)

• Blood transfusion compatibility issues (Ca²⁺ may bind citrate)

3. D5W (5% Dextrose in Water)

MOA

• Starts isotonic → becomes free water after dextrose is metabolized

• Expands intracellular fluid (ICF)

• Hydrates cells

Indications

• Hypernatremia

• Dehydration with high sodium

• Free water replacement

• Hypoglycemia (mild)

Contraindications / Cautions

• Do NOT use for resuscitation

• Increased ICP (goes into brain cells → swelling)

• SIADH

• Hyperglycemia

• Fluid overload

4. Half Normal Saline (0.45% NaCl)

MOA

• Hypotonic

• Hydrates cells (ICF)

• Some ECF expansion

Indications

• Hypernatremia

• Severe dehydration when cells are dehydrated

• Maintenance fluid for mild GI losses

Contraindications / Cautions

• Increased ICP

• Burns

• Trauma

• Liver disease

• Risk of worsening hyponatremia

5. Hypertonic Saline (3%, 5%, 7% NaCl)

MOA

• Draws water out of cells → into bloodstream

• Expands intravascular volume, reduces cerebral edema

Indications

• Severe hyponatremia

• Increased ICP / cerebral edema

• SIADH

Contraindications / Cautions

• Must be given through central line (except 3%)

• Risk of central pontine myelinolysis if sodium rises too fast

• Pulmonary edema

• Heart failure

• Renal failure

II. DEXTROSE COMBINED FLUIDS

6. D5NS (5% Dextrose in Normal Saline)

MOA

• Hypertonic

• Expands ECF and provides calories

Indications

• Hypovolemia + hypoglycemia

• Temporary TPN substitute

• Dehydration requiring glucose + sodium

Contraindications

• Renal or heart failure

• Hypernatremia

• Hyperglycemia

• Increased ICP

7. D51/2NS (5% Dextrose + 0.45% Saline)

MOA

• Slightly hypertonic

• Provides free water + sodium + glucose

• Maintenance fluid

Indications

• Most common maintenance IV fluid

• Post-op hydration

• Mild sodium-loss dehydration

Contraindications

• Hypernatremia

• Increased ICP

• DKA (not initial)

• SIADH

• Heart/kidney failure

8. D5LR

MOA

• Hypertonic version of LR

• Provides electrolytes + glucose

• Expands intravascular volume

Indications

• Burns

• GI fluid loss when glucose is needed

• Pre-surgery in certain patients

Contraindications

• Liver failure

• Hyperglycemia

• Hyperkalemia

• Increased ICP

III. COLLOIDS

(rarely used but important for exams)

9. Albumin (5%, 25%)

MOA

• Large protein solution → stays in intravascular space

• Pulls water from tissues → plasma

• Increases oncotic pressure

Indications

• Burns

• Hepatorenal syndrome

• Severe hypoalbuminemia

• Volume expansion in cirrhosis

• Third-spacing

Contraindications

• Heart failure

• Renal failure

• Active bleeding

• Costly and can cause anaphylaxis

10. Dextran / Gelatin Solutions

MOA

• Synthetic volume expanders

• Increase intravascular volume

Indications

• Rarely used except in trauma (not common in US)

Contraindications

• Coagulopathy

• Renal failure

• Anaphylaxis risk

IV. Balanced Solutions (Newer / ICU-focused)

11. Plasma-Lyte / Normosol

MOA

• Balanced crystalloid similar to plasma

• Contains acetate + gluconate (metabolized to bicarbonate)

Indications

• Sepsis

• ICU fluid resuscitation

• Metabolic acidosis

• Trauma

• Better than NS for kidney perfusion

Contraindications

• Hyperkalemia

• Severe alkalosis

Master Summary Table

Fluid	Type	Indications	Contraindications	MOA
NS	Isotonic	Shock, dehydration, hyponatremia	HF, metabolic acidosis	Expands ECF
LR	Isotonic	Burns, trauma, surgery	HyperK, liver failure	ECF expansion + buffer
D5W	Hypotonic (after metabolism)	Hypernatremia, dehydration	ICP ↑, seizures	Free water → ICF
1/2NS	Hypotonic	Hypernatremia, dehydration	Burns, trauma, ↑ICP	Hydrates cells
3% Saline	Hypertonic	Severe hyponatremia, cerebral edema	HF, renal fail	Pulls fluid out of cells
D5NS	Hypertonic	Hypovolemia + low sugar	HTN, HF	ECF expansion + calories
D51/2NS	Hypertonic	Maintenance fluid	SIADH, ↑ICP	ECF + free water
D5LR	Hypertonic	Burns, GI loss	Liver failure	ECF + electrolytes + glucose
Albumin	Colloid	Burns, cirrhosis, shock	HF, renal fail	Oncotic pull
Plasma-Lyte	Balanced	ICU, sepsis	HyperK	Balanced ECF expansion

Medications 💊

1. Acetaminophen (Tylenol)

Mechanism

• Weak central (CNS) COX inhibitor

• Increases pain threshold

• Antipyretic via hypothalamus

• NOT anti-inflammatory

Targets

• CNS (brain)

• Liver (metabolism)

Major Considerations

• Hepatotoxic at > 4 g/day (2 g/day if alcoholic or liver disease)

• Monitor LFTs

• Antidote: N-Acetylcysteine (NAC)

• Safe in pregnancy

• Does NOT irritate stomach or cause bleeding

2. Aspirin (ASA)

Mechanism

• Irreversible inhibition of COX-1 and COX-2

• Blocks thromboxane A2 → prevents platelet aggregation

Targets

• Platelets

• GI tract

• Kidneys

• CNS (fever)

Major Considerations

• Bleeding risk (irreversible platelet inhibition for 7 days)

• Avoid in children → Reye syndrome

• Avoid in ulcers, GI bleed

• Watch for salicylate toxicity (tinnitus, metabolic acidosis)

3. Ibuprofen (NSAIDs)

Mechanism

• Reversible COX-1/COX-2 inhibition

• Anti-inflammatory, analgesic, antipyretic

Targets

• Peripheral tissues (inflammation)

• Kidneys

• GI tract

Major Considerations

• Nephrotoxicity

• GI irritation/ulcers

• ↑ BP and fluid retention

• Avoid with kidney injury

• Avoid in pregnancy (3rd trimester: closes fetal ductus arteriosus)

4. Tamsulosin (Flomax)

Mechanism

• α1A blocker in prostate & bladder neck → relaxes smooth muscle → improves urine flow

Targets

• Prostate

• Bladder neck

Major Considerations

• Orthostatic hypotension → fall risk

• First-dose syncope

• Retrograde ejaculation

• Give 30 min after same meal daily

• Caution with PDE5 inhibitors (sildenafil)

5. Ondansetron (Zofran)

Mechanism

• 5-HT3 serotonin receptor antagonist

• Blocks nausea/vomiting signals in brain and GI

Targets

• Chemoreceptor trigger zone (CTZ)

• Vagus nerve in GI tract

Major Considerations

• QT prolongation

• Risk of serotonin syndrome with SSRIs

• Give IV slowly (risk of arrhythmias)

• Headache & constipation

6. Montelukast (Singulair)

Mechanism

• Leukotriene receptor blocker

• Reduces inflammation and bronchoconstriction

• Maintenance asthma med (not for acute attack)

Targets

• Bronchi

• Immune cells (eosinophils, mast cells)

Major Considerations

• Black box: neuropsychiatric effects
  (anxiety, nightmares, depression)

• Take at night

• Not for acute bronchospasm

7. Oxycodone (Opioid Analgesic)

Mechanism

• Mu-opioid receptor agonist

• Blocks pain transmission in CNS

Targets

• Brain

• Spinal cord

• GI tract (slows motility)

Major Considerations

• Respiratory depression

• Constipation (treat with stimulant laxative)

• Sedation → fall risk

• Risk of dependence

• Avoid mixing with alcohol, benzos

• Antidote: Naloxone

8. Scopolamine

Mechanism

• Muscarinic antagonist

• Blocks acetylcholine in the vestibular system → stops motion sickness

Targets

• CNS vomiting center

• Parasympathetic nervous system

Major Considerations

• Patch lasts 72 hours

• Causes dry mouth, blurry vision, urinary retention

• Avoid in glaucoma (increases IOP)

• Remove old patches before applying new ones

9. Atropine

Mechanism

• Muscarinic receptor blocker

• ↑ HR by blocking vagus nerve

• Dries secretions

• Used in organophosphate poisoning

Targets

• Heart (SA node)

• Eyes

• Salivary and sweat glands

Major Considerations

• Tachycardia

• Urinary retention

• “Hot as a hare, dry as a bone, blind as a bat”

• Avoid in glaucoma (raises intraocular pressure)

10. Glaucoma Medications

A. Timolol (beta-blocker)

• ↓ aqueous humor production

• Target: ciliary body

• Watch for bradycardia, bronchospasm

B. Latanoprost

• ↑ aqueous humor outflow

• Target: uveoscleral pathway

• Side effect: iris color darkening, eyelash growth

C. Acetazolamide

• Carbonic anhydrase inhibitor → ↓ aqueous humor

• Watch for metabolic acidosis

D. Pilocarpine

• Muscarinic agonist → ↑ drainage

• Can cause miosis, headache

11. Gabapentin

Mechanism

• Blocks voltage-gated calcium channels

• Reduces excitatory neurotransmitter release

• Used for neuropathic pain & seizures

Targets

• CNS

• Dorsal horn neurons

Major Considerations

• Sedation

• Dizziness

• Ataxia

• Adjust dose in kidney disease

• NOT metabolized by liver

12. Carbidopa (in Carbidopa/Levodopa)

Mechanism

• Carbidopa inhibits peripheral dopa decarboxylase

• Allows more levodopa to reach the brain to become dopamine

• Reduces nausea from levodopa

Targets

• Peripheral tissues (GI tract, liver)

• Allows levodopa to act in brain (basal ganglia)

Major Considerations

• Take on empty stomach

• Avoid high-protein meals (↓ absorption)

• Dyskinesias over time

• Orthostatic hypotension

• Hallucinations (dopamine effect)

Summary Table (Fast Reference)

Drug	Target	Mechanism	Key Considerations
Tylenol	CNS	COX inhibition	Liver toxicity
Aspirin	Platelets	Irreversible COX block	Bleeding, ulcers
Ibuprofen	Peripheral tissues	COX block	Kidney injury
Flomax	Prostate	α1A block	Hypotension
Zofran	CTZ/GI	5-HT3 block	QT prolongation
Montelukast	Bronchi	Leukotriene block	Neuropsych effects
Oxycodone	CNS	Mu agonist	Respiratory depression
Scopolamine	CNS	Anticholinergic	Dry mouth, glaucoma
Atropine	Heart	Anticholinergic	Tachycardia, retention
Timolol	Eye	↓ Aqueous humor	Bradycardia
Gabapentin	CNS	Ca²⁺ channel block	Sedation
Carbidopa	Peripheral	DDC inhibitor	Nausea, dyskinesia

Meds MOA

Respiratory (common drugs — indication → MOA)

• Albuterol / Salbutamol (SABA) — reliever for asthma/COPD exacerbations → β₂-adrenergic receptor agonist → bronchodilation via increased cAMP in airway smooth muscle.

• Levalbuterol — same indications → R-enantiomer of albuterol; β₂-agonist.

• Salmeterol / Formoterol (LABA) — long-term control of asthma/COPD → long-acting β₂-agonists producing sustained bronchodilation.

• Ipratropium (SAMA) — COPD/asthma adjunct reliever → muscarinic (M3) receptor antagonist → reduces bronchoconstriction.

• Tiotropium (LAMA) — maintenance COPD/asthma adjunct → long-acting muscarinic antagonist.

• Inhaled corticosteroids (e.g., budesonide, fluticasone) — controller therapy for asthma → reduce airway inflammation via glucocorticoid receptor-mediated gene transcription changes.

• Montelukast / Zafirlukast (leukotriene receptor antagonists) — allergic asthma, exercise-induced bronchospasm → block cysteinyl leukotriene (CysLT) receptors → reduce bronchoconstriction/inflammation.

• Theophylline — (less used) COPD/asthma add-on → phosphodiesterase inhibition → ↑cAMP/bronchodilation; adenosine receptor antagonism.

• Omalizumab — moderate–severe allergic asthma (IgE-driven) → anti-IgE monoclonal antibody → prevents IgE binding to receptors.

• Mepolizumab / Reslizumab (anti-IL-5) — eosinophilic asthma → monoclonal antibodies against IL-5 → reduce eosinophil activation/survival.

• Roflumilast — severe COPD with chronic bronchitis → selective PDE4 inhibitor → reduces inflammation.

Cardiac / Antihypertensive (common drugs — indication → MOA)

• ACE inhibitors (eg, lisinopril, enalapril) — HTN, HF, post-MI, nephropathy → inhibit angiotensin-converting enzyme → ↓Ang II → vasodilation, ↓aldosterone.

• ARBs (eg, losartan, valsartan) — HTN, HF → block AT₁ receptor → similar end effects to ACEIs but no bradykinin increase.

• Beta-blockers (eg, metoprolol, carvedilol, atenolol) — HTN, angina, arrhythmia, heart failure (select drugs) → antagonize β₁/β₂ receptors → ↓HR, contractility, and sympathetic drive.

• Calcium channel blockers (DHP: amlodipine; non-DHP: verapamil, diltiazem) — HTN, angina, rate control → inhibit L-type Ca²⁺ channels → vasodilation (DHP) or ↓AV nodal conduction (non-DHP).

• Diuretics:

  • Thiazides (e.g., hydrochlorothiazide) — HTN, edema → inhibit Na⁺/Cl⁻ transporter in DCT → natriuresis.

  • Loop (e.g., furosemide, bumetanide) — edema, acute pulmonary edema → inhibit NKCC2 in thick ascending limb → potent diuresis.

  • K⁺-sparing (spironolactone, eplerenone; amiloride, triamterene) — HF, hyperaldosteronism → aldosterone antagonists or ENaC blockers.

• Hydralazine — severe HTN, HF (with nitrates) → direct arteriolar vasodilator (vascular smooth muscle relaxation).

• Nitrates (nitroglycerin, isosorbide dinitrate) — angina → NO donor → ↑cGMP → venodilation (↓preload) and some coronary vasodilation.

• Digoxin — systolic HF (rate control in AF) → inhibits Na⁺/K⁺ ATPase → ↑intracellular Ca²⁺ → positive inotropy; vagomimetic effect slows AV conduction.

• Statins (eg, atorvastatin) — hyperlipidemia, ASCVD prevention → inhibit HMG-CoA reductase → ↓cholesterol synthesis, upregulate LDL receptors.

• Antiplatelet/anticoagulants (see vascular/antithrombotic section)

Neuro / Neurology (common drugs — indication → MOA)

• Levodopa + carbidopa — Parkinson disease motor symptoms → levodopa is dopamine precursor; carbidopa inhibits peripheral dopa decarboxylase to increase CNS availability.

• Dopamine agonists (pramipexole, ropinirole) — Parkinson’s → directly stimulate dopamine receptors (D2 agonists).

• Antiepileptics (representative):

  • Phenytoin — focal and generalized tonic-clonic seizures → blocks voltage-gated Na⁺ channels (use-dependent).

  • Carbamazepine — focal seizures, trigeminal neuralgia → Na⁺ channel blocker.

  • Valproate — generalized seizures, bipolar → multiple: ↑GABA, Na⁺ channel inhibition, T-type Ca²⁺ block.

  • Levetiracetam — adjunct in many seizure types → binds SV2A synaptic vesicle protein (modulates neurotransmitter release).

  • Lamotrigine — focal & generalized seizures, bipolar → Na⁺ channel blocker; inhibits glutamate release.

• Benzodiazepines (diazepam, lorazepam) — acute seizures, anxiety → GABA_A receptor positive allosteric modulators → ↑Cl⁻ influx/hyperpolarization.

• Opioids (morphine, fentanyl) — severe pain → μ-opioid receptor agonists → inhibit ascending pain pathways, alter perception.

• Migraine agents:

  • Triptans (sumatriptan) — acute migraine → 5-HT₁B/1D agonists → cranial vasoconstriction + inhibit trigeminal neurotransmission.

  • Topiramate, propranolol — migraine prophylaxis → multiple MOAs (topiramate: Na⁺ channels, GABA ↑; propranolol: β-blockade).

• Acetylcholinesterase inhibitors (donepezil, rivastigmine) — Alzheimer’s symptomatic therapy → inhibit acetylcholinesterase → ↑ACh at synapses.

Gastrointestinal (GI) meds (common drugs — indication → MOA)

• Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) — GERD, peptic ulcer, Zollinger-Ellison → irreversible H⁺/K⁺-ATPase inhibition in parietal cells → ↓acid secretion.

• H2 blockers (ranitidine [withdrawn in many places], famotidine) — peptic disease, GERD → H₂ receptor antagonists → ↓histamine-mediated acid secretion.

• Antacids (MgOH, AlOH, CaCO₃) — symptomatic heartburn → neutralize gastric acid chemically.

• Sucralfate — stress ulcers, mucosal protection → forms viscous adhesive barrier on ulcer sites.

• Bismuth subsalicylate — diarrhea, H. pylori regimens adjunct → topical GI mucosal effect; antimicrobial effects.

• Laxatives: osmotic (PEG), stimulant (senna), bulk-forming (psyllium) → various mechanisms (water retention, peristalsis stimulation, fiber bulking).

• Antiemetics:

  • Ondansetron — chemo/N/V → 5-HT₃ receptor antagonist.

  • Metoclopramide — gastroparesis, antiemetic → D₂ antagonist + prokinetic via 5-HT₄ agonism.

Endocrine (common drugs — indication → MOA)

• Insulins (rapid: lispro/aspart; short: regular; intermediate: NPH; long: glargine/detemir/degludec) — T1DM & many T2DM cases → exogenous insulin binds insulin receptor (RTK) → ↑glucose uptake/glycogen synthesis, ↓gluconeogenesis.

• Metformin — first-line T2DM → decreases hepatic gluconeogenesis, improves peripheral insulin sensitivity (AMPK activation contribution).

• Sulfonylureas (glipizide, glyburide) — T2DM → close pancreatic β-cell K_ATP channels → insulin release.

• GLP-1 receptor agonists (exenatide, liraglutide) — T2DM, weight loss adjunct → incretin mimetics → ↑glucose-dependent insulin secretion, ↓glucagon, slow gastric emptying.

• DPP-4 inhibitors (sitagliptin) — T2DM → inhibit DPP-4 → ↑endogenous GLP-1 levels.

• SGLT2 inhibitors (empagliflozin, canagliflozin) — T2DM, HF benefits → inhibit renal SGLT2 → ↑glycosuria → lower glucose and mild diuresis.

• Levothyroxine (T4) — hypothyroidism → synthetic thyroxine → replaces thyroid hormone.

• Antithyroid (methimazole, propylthiouracil) — hyperthyroidism → inhibit thyroid peroxidase (and PTU also reduces peripheral T4→T3 conversion).

• Oral corticosteroids (prednisone) — many endocrine/immunologic indications → glucocorticoid receptor agonists altering gene transcription.

Vascular / Antithrombotic (common meds — indication → MOA)

• Aspirin (low dose) — arterial thrombosis prevention → COX-1 irreversible inhibition in platelets → ↓TXA₂ → reduced platelet aggregation.

• P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) — ACS, stent → inhibit platelet P2Y12 ADP receptor → prevent platelet activation/aggregation.

• Heparin (UFH) & LMWH (enoxaparin) — VTE prophylaxis/tx, ACS → potentiate antithrombin → inhibit thrombin (IIa) and Xa (LMWH mainly Xa).

• Warfarin — chronic anticoagulation (VTE, A-fib) → inhibits vitamin K epoxide reductase → ↓γ-carboxylation of factors II, VII, IX, X.

• Direct oral anticoagulants (DOACs):

  • Dabigatran — direct thrombin inhibitor (IIa).

  • Rivaroxaban / Apixaban / Edoxaban — direct factor Xa inhibitors.

• Thrombolytics (alteplase) — acute MI, ischemic stroke (selected) → recombinant tPA → converts plasminogen to plasmin → fibrinolysis.

Antibiotics (common classes with typical indications → MOA)

• Penicillins (penicillin G/V, amoxicillin) — many Gram-positive infections, some Gram-negative → inhibit transpeptidase (PBPs) → block cell-wall peptidoglycan crosslinking (bactericidal).

• Beta-lactam + β-lactamase inhibitors (amoxicillin/clavulanate) — extend spectrum vs β-lactamase producers → same cell-wall MOA.

• Cephalosporins (cefazolin, ceftriaxone, cefepime) — broad spectrum depending on generation → inhibit cell-wall synthesis (PBPs).

• Carbapenems (meropenem) — serious multidrug infections → inhibit cell-wall synthesis (broadest β-lactams).

• Macrolides (azithromycin, erythromycin) — atypical pneumonia, STIs → bind 50S ribosomal subunit → inhibit protein synthesis (bacteriostatic/cidal concentration-dependent).

• Tetracyclines (doxycycline) — acne, tick-borne, atypicals → bind 30S ribosomal subunit → block tRNA attachment (bacteriostatic).

• Aminoglycosides (gentamicin, tobramycin) — severe Gram-negative infections (with β-lactam) → bind 30S → cause misreading and inhibit initiation (bactericidal, oxygen-dependent uptake).

• Fluoroquinolones (ciprofloxacin, levofloxacin) — broad Gram-negative/atypical coverage → inhibit DNA gyrase (topo II) and topoisomerase IV → impair DNA replication.

• Vancomycin — MRSA, serious Gram-positive infections → binds D-Ala-D-Ala → inhibits cell-wall peptidoglycan polymerization (bactericidal).

• Metronidazole — anaerobic infections, C. difficile → nitroimidazole reduced in anaerobes → DNA strand breakage.

• Linezolid — VRE, MRSA alternatives → binds 50S subunit at the initiation complex → prevents protein synthesis.

Psychiatric medications (common classes/drugs — indication → MOA)

• SSRIs (fluoxetine, sertraline, citalopram, escitalopram, paroxetine) — depression, anxiety, OCD, PTSD → inhibit serotonin reuptake transporter (SERT) → ↑synaptic 5-HT.

• SNRIs (venlafaxine, duloxetine) — depression, neuropathic pain, anxiety → inhibit serotonin and norepinephrine reuptake transporters.

• TCAs (amitriptyline, nortriptyline) — depression, neuropathic pain → inhibit reuptake of 5-HT and NE; block many other receptors (anticholinergic, antihistamine).

• MAO inhibitors (phenelzine, tranylcypromine) — atypical depression (rare use) → inhibit monoamine oxidase → ↑NE, 5-HT, dopamine (risk of tyramine interactions).

• Atypical antipsychotics (risperidone, olanzapine, quetiapine, clozapine) — schizophrenia, bipolar → D₂ (and variable 5-HT₂A) receptor antagonism/partial agonism; clozapine reserved for refractory schizophrenia.

• Typical antipsychotics (haloperidol)-psychosis, acute agitation → D₂ receptor antagonists.

• Mood stabilizers:

  • Lithium--bipolar disorder maintenance → multiple proposed MOAs (modulates second-messenger systems, inositol monophosphatase inhibition).

  • Valproate-- bipolar mania → increases GABA, modulates Na⁺ channels.

• Benzodiazepines (alprazolam, lorazepam)- acute anxiety, insomnia, seizures → GABA_A positive allosteric modulation.

• Buspirone-generalized anxiety → 5-HT1A partial agonist (non-benzodiazepine anxiolytic).

Opinion: Elections Don’t Choose Leaders-They Manufacture Consent

By Ronnie Law

I recent years, I’ve come to believe something uncomfortable, something most people sense but rarely say out loud: our elections don’t elect our leaders ruling over us. Not real ones. Not the people who actually run anything of consequence. In 2025, political power isn’t determined by ballots or debates. It’s shaped behind closed doors, enforced through leverage, blackmail, pressure campaigns, and the kind of kompromat that never sees daylight.

The story we are told, the story of democracy, is that ordinary citizens choose their leaders, send them into office, and those leaders faithfully exercise power on the people’s behalf. But look around. Watch what happens when an elected official steps out of line. Tell the wrong truth, defend the wrong person, criticize the wrong institution, or refuse to play along with the expectations of the real power brokers. Within hours, the gears begin to turn: media firestorms, donor pressure, intelligence leaks, institutional revolt, “investigations,” and a level of public humiliation that no voting booth can prevent.

This is not the behavior of a system run by voters. Certainly not democratic. Some of us I tired of lies and deception.
This is the behavior of a system run by leverage.

The real purpose of modern elections is psychological, not political. The system needs our participation, not our power. Voting is the ritual that gives people the illusion that they are in control, that they have a stake, that they are choosing something meaningful.

But the essence of elections today is simply this:
to obtain the consent of the governed.

It’s a formalized process of public validation for decisions already made elsewhere, by networks of donors, bureaucrats, lobbyists, intelligence insiders, media institutions, and transnational alliances that no voter can touch.

People imagine democracy as choosing who will govern them.
But in practice, it’s closer to giving your signature at the bottom of a contract you didn’t write.

Participation becomes submission.
Turnout becomes compliance.
The ballot becomes a permission slip.

In this system, the most powerful people almost never run for office. They don’t need to. Their influence comes from invisible sources:

• the funding that makes or breaks campaigns

• the information they can leak or conceal

• the networks they can activate against a politician

• the economic pressure they can apply

• the institutional alliances they can weaponize

A senator or governor might think they represent their voters. But the moment they cross the unwritten red lines of the system, they are reminded-swiftly, who actually has the ability to end careers.

To put it bluntly: blackmail governs more than ballots.
Compromise governs more than constitutions.

And elections serve as a stage play to reassure the public that nothing is wrong. Rule by consent becomes rule by persuasion-And rule by persuasion becomes rule by perverts.

Some political theorists call this “managed democracy.” Others call it “soft authoritarianism.” I call it something simpler: rule by consent that is manufactured, not earned.

Or, as an older political term puts it: rule by perverts, a society where those with informal power, backroom influence, and private leverage shape the official decisions of public officials.

This isn’t a conspiracy theory. It’s a pattern. Don't take my word for it, just look around. 

Every time a leader bows to pressure campaigns instead of voters, the mask slips.

Every time someone resigns not because of an election but because the right people made the right phone calls, the mask slips.
Every time public outrage is orchestrated to punish a dissenting voice, the mask slips.

The result is a political system that looks democratic on its face but oligarchic underneath, responsive to pressure, not principles.

So what do elections really do? They maintain the ritual. The appearance. The sense of participation necessary to keep the public calm. People go to the polls thinking they have chosen the direction of the nation. But in reality, they have only ratified the legitimacy of a structure they do not control.

And the real leaders-the unelected ones-continue their work quietly, untouched by the vote tally.

The first step toward political maturity is admitting the obvious:
Elections are no longer instruments of power. They are instruments of consent.

The real struggle of our time is not between left and right, red and blue, liberal and conservative. It is between the appearance of democracy and the reality of influence.

We are governed-yes-but not by the people we think we elect.
And until we confront that truth, the illusions will continue, year after year, cycle after cycle. 

Democracy is no longer a system of choosing leaders.
It has become a system of choosing and reinforcing beliefs.

And the belief most fiercely protected is the myth that elections still matter in the way we wish they did.

On the Dog that Refused to Bark J.E and D.J.T

The Dog That Didn’t Bark: Rethinking the Epstein–Trump Email and the Possibility of Intelligence Ties

For years, the public has combed through every scrap of information connected to Jeffrey Epstein, Ghislaine Maxwell, and the names orbiting their world. But one email from April 2, 2011, has been widely misinterpreted—and may hold a far more provocative implication than people realize.

In that message, Epstein wrote privately to Maxwell:

“I want you to realize that the dog that hasn’t barked is Trump. This particular victim… spent hours at my house with him. He has never once been mentioned, police chief, etc. I’m 75% there.”

Maxwell replied:

“I have been thinking about that…”

Most readers assume Epstein meant Trump himself wasn’t saying anything. But that reading ignores the literary allusion Epstein is clearly invoking—and the implications behind it.

1. “The Dog That Didn’t Bark” — What Epstein Actually Meant

The phrase comes from a Sherlock Holmes story, in which a dog’s failure to bark during a break-in reveals that the intruder was someone familiar.

In other words, the absence of expected evidence is itself evidence.

Epstein appears to be making the same point:

• A victim (almost certainly Virginia Giuffre)

• Who spent hours with Trump

• Has never named him

• Even though Epstein claims to have personal knowledge suggesting she should

Epstein is saying this absence is suspicious, not reassuring. He expected Trump’s name to surface—and the fact that it didn’t set off alarm bells.

2. Why Would Trump’s Silence—or Protection—Matter to Epstein?

Epstein’s mention of the “police chief” indicates he’s connecting this to the earlier 2008 investigation, the one that resulted in Epstein’s infamous sweetheart deal.

By 2011, Epstein is trying to re-enter elite social circles post-arrest. He is monitoring who has spoken, who hasn’t, and who may be protected. The tone of his emails shows him:

• Wheeling and dealing information

• Tracking who can be compromised

• Looking for leverage to rebuild social capital

So when Trump—a man Epstein says should be implicated—remains untouched, Epstein wonders why.

Was he paid off?
Was someone protecting him?
Was this evidence of a larger intelligence connection?

3. Epstein’s Incriminating Pattern: Information as Currency

Another email exchange years later adds context.

In 2015, a mutual associate (Wolf) warns Epstein that CNN will ask about his relationship with a certain public figure. Epstein suggests “crafting” an answer for him. Wolf replies that if the figure lies—claiming he’d never flown with Epstein—Epstein could use that lie as leverage:

• Expose him, regaining public sympathy

• Or keep the truth hidden, creating a debt and securing influence

Wolf even notes:

“He’s absolutely been on the plane. Look at my logs.”

This shows Epstein’s mindset:
Information = power. Leverage. Insurance.

So the Trump anomaly in the 2011 email fits perfectly into Epstein’s worldview. If someone should be named and isn’t, there must be a structural reason.

4. Did Epstein Suspect Trump Was Being Protected by Intelligence?

Alexander Acosta famously claimed in 2019 that he was told Epstein “belonged to intelligence,” which was used to justify the 2008 lenient plea deal.

If Epstein knew—or suspected—that:

• he was intelligence-linked, and

• other names in his orbit also enjoyed protection

…then Trump’s immunity in the victim’s statements may have confirmed his fears. Epstein says he is “75% there” in the email. That is the language of someone forming a hypothesis, not stating a fact.

His theory may have been something like:

• Trump was involved.

• The victim knew it.

• Law enforcement also knew it.

• Yet everyone stayed silent.

Why?
Perhaps because Trump, too, was tied to the same machinery of protection.

5. The Technocrat’s Ideal Candidate: Dirt as Leverage

Now shift scenes entirely—into political theory.

If a technocrat, oligarch, or foreign intelligence service wanted to install a controllable president, who would be the perfect target?

• A celebrity

• A household name

• Someone with a well-known brand

• Someone with broad public familiarity

• Someone with … existing blackmail vulnerabilities

A person with deep, life-destroying dirt on them is an ideal asset, because:

1. You don’t need to manufacture leverage.

2. The threat of exposure ensures obedience.

3. The kompromat becomes a permanent tether.

This line of reasoning connects, hypothetically, to Epstein’s files.
People ask:

“If you’re covering everything up, why not just destroy the files?”

Because destroyed files have no value.
Preserved files = perpetual leverage.

If someone with that kind of leverage helped facilitate a political rise, they would never destroy the evidence tying that person to them.

6. What If the Relationship Eventually Fractured?

Imagine you successfully use such a person to gain the presidency.
Then imagine:

• He loses once.

• Runs again.

• Starts saying: “This time is different because I had the wrong people around me.”

• Suggests he will act independently next time.

To his handlers, this might be tolerable—until he actually wins again.
And then begins acting like he’s no longer bound.

Suddenly, he’s:

• Purging documents

• Ordering agencies to wipe or redact his involvement

• Believing he has insulated himself

At that point, what would the controlling power do?

They would leak.
Strategically.
Not enough to detonate everything—just enough to remind him who owns him.

This is the logic of leverage, blackmail, and statecraft—not fantasy.

7. The Epstein Email as an Early Data Point

None of this “proves” anything.
But the 2011 email fits a pattern:

• Epstein was confused that Trump wasn’t named.

• Epstein believed the victim had personal interactions with him.

• Epstein connected this to law enforcement silence.

• Epstein saw it as suspicious—“the dog that didn’t bark.”

A name that should have appeared was absent.
And in the world Epstein lived in, absences were rarely accidental.

Conclusion

This analysis isn’t claiming a grand unified theory.
But the email does seem to show:

• Epstein was suspicious about Trump’s unexplained protection.

• He was aware of leverage, kompromat, and intelligence ties.

• He believed silence in the record was evidence, not absence.

• And the world of oligarchic influence makes such silence meaningful.

If Epstein suspected Trump was being shielded—not just by money or lawyers but by something systemic—then the 2011 message reads very differently from the shallow interpretations circulating today.

Sometimes the most important clue is the one that never gets mentioned.
The dog that didn’t bark.

Field Notes November 13th

SBAR #74

Situation:
30-year-old male with schizoaffective disorder, history of paranoid delusions and violent threats, recently released from incarceration, presented from APT Foundation with altered mental status (AMS), tremors, tachycardia, and hypertension.

Background:
CT head and EEG negative; ammonia mildly elevated, ethanol level 11; TSH normal; CK mildly elevated. Suspected acute psychosis likely due to medication noncompliance during transition from correctional to psychiatric care.

Assessment:

• A&Ox4

• Room air

• AMS with tremors and hypertension likely secondary to abrupt Depakote cessation.

• Psychosis stable on Olanzapine 5 mg BID with sitter for violent ideation.

• Low urine output (urinary retention); mild leukocytosis without infection source.

• Hypertension stable on Lisinopril; switching Clonidine to Propranolol for tremor and BP control.

• Chest pain resolved; ECG/troponin negative.

Recommendation:

1. Continue 1:1 sitter for safety.

2. Continue Olanzapine 5 mg BID; monitor urinary retention.

3. Continue Propranolol 10 mg TID (for tremor, tachycardia).

4. Continue IV fluids and bladder scans q6h; straight cath PRN.

5. Trend LFTs and CBC.

6. Continue Lisinopril for HTN.

7. Coordinate with psych for med reconciliation with Garner Facility.

Rationale for interventions:

• 1:1 sitter: Prevents self-harm or violence during acute psychosis.

• Olanzapine: Antipsychotic for mood stabilization and psychosis control.

• Monitor urinary retention: Anticholinergic side effect of Olanzapine.

• Propranolol: Nonselective β-blocker reduces tremors and sympathetic overactivity.

• IV fluids & bladder scans: Support renal perfusion, treat retention, prevent AKI.

• Trend LFTs/CBC: Detect medication-induced hepatic or hematologic effects.

• Psych coordination: Ensures accurate continuation of prior regimen, reducing relapse risk.

SBAR #73

Situation:
71-year-old male with CAD (s/p LAD PCI 2017), HTN, HLD, MDD, and vascular dementia presented with worsening confusion; self-called 911.

Background:
Lives alone after sister moved out. Son reports progressive paranoia and hallucinations. CT head negative; chest x-ray with possible opacity; platelets low (73); alkaline phosphatase elevated; otherwise stable.

Assessment:
Likely progression of vascular dementia. No infection, electrolytes normal, afebrile, and hemodynamically stable. Mild chronic liver enzyme elevation and new thrombocytopenia.

Recommendation:

1. Admit to medicine for observation.

2. Continue trazodone 25 mg HS for agitation/sleep.

3. Continue cardiac meds (ASA, metoprolol, Imdur).

4. Continue Lexapro 10 mg daily for depression.

5. Check GGT to assess liver source of ALP elevation.

6. Monitor CBC for thrombocytopenia trend.

7. Cardiac diet and fall precautions.

8. Confirm home meds with son.

Rationale for interventions:

• Admission: Allows monitoring of mental and medical status in safe environment.

• Trazodone: Sedating antidepressant used for sleep and agitation in dementia.

• Cardiac meds: Prevent angina or MI recurrence.

• Lexapro: Maintains mood stability; depression can worsen cognition.

• GGT test: Distinguishes liver vs. bone etiology of elevated ALP.

• CBC monitoring: Detects progression of thrombocytopenia or bleeding risk.

• Cardiac diet: Controls hypertension and CAD progression.

• Home med verification: Ensures accuracy and prevents drug duplication or omission.

SBAR #64

Situation:
69-year-old male with asthma, COPD, CAD s/p PCI, HFpEF, alcohol use disorder, and HTN admitted for acute hypoxemic respiratory failure and alcohol withdrawal.

Background:
Drinks 1 pint of vodka daily. On Valium taper for withdrawal. Weaned off oxygen.

Assessment:
Improving respiratory status, stable vitals, mild hypertension. No active withdrawal symptoms.

Recommendation:

1. Continue prednisone 40 mg daily ×5 days.

2. Continue Symbicort and Spiriva inhalers.

3. Continue Valium taper for alcohol withdrawal.

4. Follow up on echocardiogram results.

Rationale for interventions:

• Prednisone: Reduces airway inflammation in COPD exacerbation.

• Symbicort (ICS/LABA): Improves airflow and reduces exacerbation frequency.

• Spiriva (LAMA): Maintains bronchodilation and decreases mucus hypersecretion.

• Valium taper: Prevents seizures and autonomic instability during alcohol withdrawal.

• Echocardiogram: Evaluates cardiac function in setting of HFpEF and prior CAD.

SBAR #65

Situation:
54-year-old female with autoimmune disease (SLE vs. dermatomyositis), Type II DM, Crohn’s disease, bipolar disorder, chronic abdominal pain, and malnutrition—now s/p G-J tube (11/6/25).

Background:
Transferred from inpatient psychiatry for persistent vomiting, weight loss, and abdominal pain. Pain worsened after buprenorphine initiation. Refusing gabapentin/pregabalin. Evaluated by GI, psychiatry, and pain management.

Assessment:
Chronic pain likely multifactorial—functional GI component, visceral hypersensitivity, and opioid-induced hyperalgesia. Malnutrition improving on tube feeds. Mood unstable due to uncontrolled pain.

Recommendation:

1. Continue G-J tube feeds at goal rate per RD.

2. Continue Oxycodone 10 mg q4h PRN (short-term).

3. Continue Buprenorphine 8 mg TID (plan outpatient taper).

4. Continue Robaxin 1000 mg TID, lidocaine patches, capsaicin cream.

5. Continue bowel regimen: Senna, Miralax.

6. Monitor EKG for QTc prolongation on Seroquel/Fluoxetine.

7. Continue Seroquel 175 mg HS + 25 mg AM.

8. Continue Fluoxetine 40 mg daily.

9. Continue levothyroxine for hypothyroidism; recheck TSH in 6–8 weeks.

10. Continue Losartan/Toprol XL for HTN, Lispro for DM.

11. Palliative and psychiatry follow-up before discharge.

Rationale for interventions:

• Tube feeding: Provides nutritional support, prevents further catabolism.

• Oxycodone short-term: Controls breakthrough pain while preventing withdrawal.

• Buprenorphine taper plan: Minimizes dependence while treating baseline pain.

• Robaxin/lidocaine/capsaicin: Multimodal pain control reduces opioid use.

• Bowel regimen: Prevents opioid-induced constipation.

• EKG monitoring: Prevents arrhythmias from QT-prolonging meds.

• Psych meds: Stabilize mood and prevent suicidal ideation.

• Levothyroxine: Corrects hypothyroidism and supports metabolic recovery.

• Antihypertensives/insulin: Maintain BP and glycemic control during recovery.

• Palliative/psych follow-up: Coordinates symptom and mental health management.

Derivatives are Too Complex

STUDY NOTES ON: The $600 Trillion Derivatives Market

1. Overview

• The derivatives market is worth ≈ $600 trillion — over 6× global GDP (~$100 trillion).

• Warren Buffett (2003): called derivatives “financial weapons of mass destruction.”

• Nearly destroyed the world economy in 2008 (Lehman Brothers, AIG, etc.).

• Instead of reducing, the market has grown 10× since 2008.

2. What Are Derivatives?

• Definition: A financial contract whose value is derived from an underlying asset.

• Underlying asset can be: stocks, bonds, commodities, currencies, interest rates — even weather or default probability.

• Purpose:

  • Originally designed to hedge risk.

  • Now often used to speculate, creating massive leverage.

3. Main Types of Derivatives

Type	Description	Example
Futures	Bet on price of an asset at a future date.	Oil, gold, wheat.
Options	Right (not obligation) to buy/sell at a fixed price.	Stock options.
Swaps	Exchange of cash flows (e.g., fixed ↔ variable interest).	Interest rate swaps.
Forwards	Customized contracts for future purchase/sale.	Corporate hedging.

4. Use vs. Abuse

• Legitimate uses: hedging by farmers, airlines, corporations.

• Modern use: dominated by banks making leveraged bets using borrowed money.

• Leverage example:

  • $100 million swap, only $1 million collateral → 100:1 leverage.

  • A 1–2% move can wipe out collateral → systemic risk.

5. Systemic Risk and 2008 Collapse

• Credit Default Swaps (CDS): Insurance-like contracts on bond defaults.

• AIG: Sold $500B in CDS, couldn’t pay when mortgages defaulted → $180B bailout.

• Lehman Brothers: $35T in derivative exposure → failure triggered global panic.

• Result: ~$29 trillion global intervention needed to stop collapse.

6. Why Derivatives Are Dangerous

• Counterparty risk: Failure of one bank affects all others in chain.

• Complexity: Products so intricate that even creators can’t predict behavior under stress.

• Opacity: Nobody truly knows “who owes what to whom.”

• Leverage stacking: “Bets on bets” → magnified risk.

7. Aftermath & Regulation (Post-2008)

• Dodd-Frank Act (2010):

  • Introduced reporting and central clearing for some derivatives.

  • Did not reduce total size or ban risky products.

• Result:

  • Market ballooned from $60T (2008) → $600T (2025).

  • Reforms weakened by lobbying.

8. Present Composition (2025)

Type	Value	Risk
Interest rate derivatives	$500T	Sensitive to rate volatility.
Credit derivatives (CDS)	$50T	Corporate defaults → massive exposure.
Currency derivatives	$100T	Impacted by dollar instability.

9. Top 4 U.S. Holders (≈90% of Exposure)

Bank	Notional Exposure	Capital Ratio (approx.)
JP Morgan Chase	$54T	180× capital
Citibank	$48T	240× capital
Bank of America	$37T	130× capital
Goldman Sachs	$47T	390× capital

 These banks are too big to fail — and now too big to save.

10. Current Triggers of Potential Collapse

1. Interest Rate Volatility

   • Fed raised rates 0% → 5% (2021–2023).

   • Creates hidden losses in derivatives.

2. Commercial Real Estate Defaults

   • $2T in loans to refinance at higher rates → defaults → CDS payouts.

3. European Banking Stress

   • Credit Suisse collapse (2023), Deutsche Bank risk ($40T exposure).

4. Sovereign Debt Crises

   • Japan: Debt = 260% of GDP.

   • China: $13T local govt. debt, real estate collapse.

11. Why a 2008-Style Bailout Won’t Work

• Total global debt + low trust + inflation = no rescue capacity.

• Governments can’t borrow or print enough money ($60T+ needed).

• Money printing = hyperinflation & currency collapse.

• Public opposition to more bailouts = political paralysis.

12. Mathematical and Structural Limits

• Derivatives are contracts, not tangible assets — can’t be “bought out.”

• Losses of one side = gains for another → bailouts just transfer wealth to speculators.

• The market is too complex to unwind quickly; failure cascades in hours or days, not months.

13. Expected Outcome of Collapse

• Bank failures → frozen accounts.

• Credit cards, pensions stop functioning.

• Supply chains break down.

• Global depression and social unrest follow.

• Key insight: The system has outgrown the capacity to stabilize it.

14. Final Summary

• 2008: $60T derivatives → near-collapse → saved by $29T bailout.

• 2025: $600T derivatives → 10× larger → no bailout capacity left.

• Triggers active now: rate volatility, defaults, global debt stress.

• Conclusion:

  “Every financial weapon of mass destruction eventually detonates. Derivatives are no different.”